| ★ |  Rapid Evolution in GLP-1s and Therapeutics at ADA 2026 | | 171 | Estados Unidos | |
| 7 |  Diabetes Dialogue: Omnipod and AID Advancements at Insulet, With Trang Ly, PhD, MBBS | | 4.3K | Estados Unidos | 92 |
| 13 |  Retatrutide Provides Substantial Weight Loss in Patients With Obesity or Overweight | | 1.1K | Estados Unidos | 91 |
| 3 |  Diabetes Dialogue: The ADA’s Statement on Diabetes Tech Integration, With Eugene Wright Jr., MD | | 584 | Estados Unidos | 93 |
| 14 |  GLP-1 Therapies: Where We’ve Been & Where We’re Going | Conversations on Health Care @cohcpodcast | 541 | Estados Unidos | 91 |
| 10 |  Diabetes Dialogue: Retatrutide Phase 3 Data Show Major Weight Loss | | 533 | Estados Unidos | 92 |
| 15 |  TRIUMPH-2: Retatrutide Reduces Weight, A1C in Patients With Obesity | | 350 | Estados Unidos | 91 |
| 8 |  Diabetes Dialogue: Tech, Screening, and Care Highlights from ADCES 2026 | | 224 | Estados Unidos | 92 |
| 18 |  Diabetes Dialogue: Weekly Insulin Icodec Now Available for Type 2 Diabetes | | 206 | Estados Unidos | 90 |
| 17 |  Functional Cures for T1D: Insulin Independence Through Islet Transplantation | | 185 | Estados Unidos | 90 |
| 6 |  Diabetes Dialogue: CKM Systems, Triple Agonists, and a Sensor Scandal Ahead of ADA | | 179 | Estados Unidos | 92 |
| 20 |  Retatrutide Cuts Weight, Cardiovascular Disease Risk in TRIUMPH-3 | | 158 | Estados Unidos | 90 |
| 9 |  Diabetes Dialogue: Tegoprubart and Freedom from Insulin in Type 1 Diabetes | | 143 | Estados Unidos | 92 |
| 12 |  Diabetes Dialogue: Evolving Wearable Insulin Delivery Devices - AID, CGM, and More | | 139 | Estados Unidos | 91 |
| 2 |  Diabetes Dialogue: CONNECT, TRANSCEND, and TRIUMPH at ADA 2026 | | 114 | Estados Unidos | 94 |
| 5 |  Diabetes Dialogue: Diabetes Technology and Treatment in the UK, With Ketan Dhatariya, MD, PhD, MS | | 94 | Estados Unidos | 92 |
| 4 |  Diabetes Dialogue: The International Diabetes Federation and Care in India, With Amit Gupta, MBBS | | 79 | Estados Unidos | 92 |
| 1 |  Incretins, Monitors, and Insulin Titration at ADA 2026 | | 76 | Estados Unidos | 96 |
| 16 |  Diabetes Dialogue: Signos and the Science of Weight Loss | | 75 | Estados Unidos | 90 |
| 11 |  Diabetes Dialogue: Teplizumab, Stelo, and Inhaled Insulin Afrezza for Pediatric Patients | | 53 | Estados Unidos | 91 |
| 19 |  Continuous Ketone Monitoring May Guide SGLT2i Use in T1D | | 33 | Estados Unidos | 90 |